Retatrutide tracker
Retatrutide acts on three hormone receptors at once: GIP, GLP-1 and glucagon, which is why it is described as a triple agonist. In clinical trials it is given as a once-weekly injection with gradual dose increases. It is often called "GLP-3R" online, although that is shorthand, not an official name.
PRTCL keeps every Retatrutide dose in one encrypted record: the amount, the time, the injection site and the vial it came from, lined up against your sleep, heart rate and recovery from Health Connect.
| Also known as | GLP-3R |
|---|---|
| Class | Triple GIP, GLP-1 and glucagon receptor agonist (investigational) |
| US status | Investigational Investigational (not approved) |
| Last reviewed | September 2026 |
Status as of September 2026.
Retatrutide is an investigational medicine from Eli Lilly. Lilly reported Phase 3 obesity results in 2026 and has said it plans to seek FDA approval, but it is not approved anywhere yet and is legally available only inside clinical trials. Products sold online as "Retatrutide" or "GLP-3R" are unapproved and unregulated.
What people log for Retatrutide.
- Trial visit dates and the dose you were assigned, if you are in a study
- The weekly injection day and site
- Weight and activity from Health Connect over time
- Questions and notes to bring to the study team
How PRTCL handles it
- Reconstitution math: vial strength and water in, units to draw out
- Dose logging in mcg or mg, with the time and injection site
- Site rotation that suggests the next spot before you draw
- Daily, weekly, cycling and custom schedules with reminders at the times you set
- Inventory that counts down with every dose and warns before you run out
- Sleep, heart rate, steps and weight from Health Connect beside every dose
- PubMed: Retatrutide Phase 2 trial for obesity (NEJM, 2023, human trial)
- HCPLive: Retatrutide TRIUMPH-1 Phase 3 results (May 2026)
- Eli Lilly: Retatrutide Phase 3 results
- FDA: unapproved GLP-1 drugs used for weight loss
All peptides · Peptide tracker · Supplement tracker · Injection-site rotation · Bacteriostatic water · GLP-1 tracker · GLP-1 units calculator
Common questions.
Is Retatrutide FDA-approved?
No. As of September 2026, Retatrutide is investigational. Eli Lilly has reported Phase 3 results and said it plans to seek approval, but it is available only in clinical trials.
What is "GLP-3R"?
"GLP-3R" is an informal nickname used online for Retatrutide, because it acts on three hormone receptors. It is not an approved product name.
Can PRTCL track a clinical-trial protocol?
Yes. You can log the weekly dose, the injection day and site, and keep your weight and activity from Health Connect alongside it, which makes study visits easier to prepare for.
Track it in one system.
PRTCL runs peptides, supplements, nutrition and training together, with reminders at the times you set, reconstitution math, site rotation and inventory that counts itself down. Launching on Android and iPhone the same day. Join the waitlist and enter the draw for one of 57 lifetime Premium subscriptions.